Addressing the challenge of extended-spectrum beta-lactamases.

Abstract

During the last decade, community-acquired extended-spectrum beta-lactamase (ESBL)-producing bacteria, and in particular Escherichia coli producing ESBLs of the CTX-M-type, have spread worldwide. These organisms are most often isolated from the urinary tract, but have also been isolated from bacteria in the blood. Cephalosporin- and fluoroquinolone-containing treatments are the two most common risk factors identified in patients with ESBL producers. In addition, associated resistance to other classes of antimicrobial agents are often observed in CTX-M producers, limiting the availability of therapeutic options. Carbapenems should be considered as the drug of choice for treating serious systemic infections caused by ESBL-producing bacteria, but preventing the spread of and appropriately managing these infections remains difficult.

• Authors: Jean-Ralph Zahar, Olivier Lortholary, Claude Martin, Gilles Potel, Patrick Plesiat, Patrice Nordmann
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 10 Issue 2 Pg. 172-80 (Feb 2009) ISSN: 2040-3429 [Electronic] England
• PMID: 19197795 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Carbapenems
• Cephalosporins
• Fluoroquinolones
• beta-Lactams
• beta-Lactamases

Topics

• Anti-Bacterial Agents (pharmacology)
• Carbapenems (pharmacology, therapeutic use)
• Cephalosporins (pharmacology, therapeutic use)
• Community-Acquired Infections (epidemiology, microbiology)
• Drug Resistance, Multiple, Bacterial
• Escherichia coli (isolation & purification)
• Escherichia coli Infections (microbiology)
• Fluoroquinolones (pharmacology, therapeutic use)
• Humans
• Randomized Controlled Trials as Topic
• Risk Factors
• Treatment Outcome
• Urinary Tract Infections (epidemiology, microbiology)
• beta-Lactam Resistance
• beta-Lactamases (classification, genetics, metabolism)
• beta-Lactams (pharmacology)